at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
Company profile
Ticker
EXAI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Exscientia Ltd
SEC CIK
EXAI stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
22 Apr 24
424B5
Prospectus supplement for primary offering
5 Apr 24
EFFECT
Notice of effectiveness
5 Apr 24
F-3
Shelf registration (foreign)
21 Mar 24
S-8
Registration of securities for employees
21 Mar 24
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
Exscientia Business and Financial Update for the Full Year 2023
21 Mar 24
6-K
Current report (foreign)
13 Feb 24
6-K
Current report (foreign)
9 Nov 23
6-K
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
20 Sep 23
Latest ownership filings
144
Notice of proposed sale of securities
24 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
SC 13G/A
Hopkins Andrew
12 Feb 24
144
Notice of proposed sale of securities
8 Jan 24
SC 13D/A
SB Global Advisers Ltd
11 Apr 23
SC 13G/A
Hopkins Andrew
14 Feb 23
SC 13G/A
BlackRock Inc.
9 Aug 22
SC 13G
Hopkins Andrew
11 Feb 22
SC 13G
BlackRock Inc.
7 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
43.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 12 |
Closed positions | 9 |
Increased positions | 22 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 153.62 bn |
Total shares | 53.05 mm |
Total puts | 87.40 k |
Total calls | 43.90 k |
Total put/call ratio | 2.0 |
Largest owners | Shares | Value |
---|---|---|
SB Global Advisors | 18.98 mm | $0.00 |
SFTBY Softbank | 5.68 mm | $25.68 bn |
Laurion Capital Management | 5.63 mm | $25.44 bn |
Baillie Gifford & Co | 4.87 mm | $22.01 bn |
Platinum Investment Management | 4.40 mm | $19.87 bn |
Woodline Partners | 2.44 mm | $11.03 bn |
Bill & Melinda Gates Foundation | 1.59 mm | $7.19 bn |
MIC Capital Management UK | 1.54 mm | $6.97 bn |
Pictet Asset Management Holding | 1.37 mm | $6.19 bn |
Marshall Wace | 1.32 mm | $5.95 bn |
News
Morgan Stanley Maintains Equal-Weight on Exscientia, Maintains $7 Price Target
22 Apr 24
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
3 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Exscientia Earnings Preview
20 Mar 24
Press releases
Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education
18 Apr 24
Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum
16 Apr 24
AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe
11 Apr 24
Canada's Strategic Move Towards AI: An Investor and Trader's Perspective
9 Apr 24
Emerging AI Healthcare Pioneers Promise Medical Breakthroughs and Investment Opportunities (CSE: TRUE)
5 Apr 24